13.75
0.12 (0.88%)
| Penutupan Terdahulu | 13.63 |
| Buka | 14.18 |
| Jumlah Dagangan | 210,462 |
| Purata Dagangan (3B) | 183,750 |
| Modal Pasaran | 520,663,008 |
| Harga / Buku (P/B) | 41.79 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Aug 2025 - 18 Aug 2025 |
| EPS Cair (TTM) | -3.05 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 113.89% |
| Nisbah Semasa (MRQ) | 6.61 |
| Aliran Tunai Operasi (OCF TTM) | -102.25 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -62.83 M |
| Pulangan Atas Aset (ROA TTM) | -39.04% |
| Pulangan Atas Ekuiti (ROE TTM) | -115.39% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Celcuity Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 1.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 1.88 |
|
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company’s lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 13.21% |
| % Dimiliki oleh Institusi | 81.78% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 134.00 (Jefferies, 874.55%) | Beli |
| Median | 110.00 (700.00%) | |
| Rendah | 70.00 (Needham, 409.09%) | Beli |
| Purata | 105.86 (669.89%) | |
| Jumlah | 6 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 82.34 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Jefferies | 02 Dec 2025 | 134.00 (874.55%) | Beli | 97.50 |
| Wolfe Research | 18 Nov 2025 | 110.00 (700.00%) | Beli | 91.60 |
| HC Wainwright & Co. | 17 Nov 2025 | 94.00 (583.64%) | Pegang | 92.23 |
| 22 Oct 2025 | 77.00 (460.00%) | Beli | 70.04 | |
| Craig-Hallum | 13 Nov 2025 | 108.00 (685.45%) | Beli | 86.00 |
| Stifel | 13 Nov 2025 | 115.00 (736.36%) | Beli | 86.00 |
| Needham | 20 Oct 2025 | 70.00 (409.09%) | Beli | 70.58 |
| 03 Oct 2025 | 70.00 (409.09%) | Beli | 50.51 | |
| Guggenheim | 22 Sep 2025 | 110.00 (700.00%) | Beli | 52.49 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |